Research and Development

Regeneron has announced that its eye drug Eylea (aflibercept) failed its primary endpoint in a mid-stage trial investigating its effectiveness …

AstraZeneca today announced that Professor David Goldstein will join the Company in the consultative role of Chief Adviser, Genomics to …

The latest issue of Pharmafocus is now available, and with it comes Advances in Oncology, our supplement featuring all the …

Coming towards the end of September, we’ve had some major developments in drug trials and bad news for some of …

News broke on 29 September that Hanmi Pharma, South Korea’s leading drug maker, had signed a $910 million deal with …

GlaxoSmithKline PLC has named Brian McNamara the head of its consumer-health division. The new comes a week after the announcement …

AbbVie’s new Singapore based manufacturing plant is expected to be fully operational by late 2018. The plant is expected to …

The latest edition of Pharmafocus is available online now.

The British Medical Journal, after its own investigation, found that Janssen knew early into the Phase III trial, known as …

Novo Nordisk, headquartered in Bagsvaerd, Denmark, has taken the decision to lose 1,000 of its workforce from a total global …

Bayer has announced that its Eylea (aflibercept) drug has received a final recommendation from NICE for the treatment of visual …

GW Pharmaceuticals’ Epidiolex is designed to treat seizures in a rare form of epilepsy called Lennox-Gaustaut Syndrome. GW pharmaceuticals published …

The report, by GlobalData, states that the primary reasons behind this growth are linked to medical tourism, a lack of …

AbbVie and Eisai have announced the Japanese approval of a new indication for the former’s anti-TNF-α monoclonal antibody formulation Humira …

Zuckerberg and Chan have committed $3 billion of their own money to setting up the health initiative that has an …